{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:29:42Z","timestamp":1775946582856,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T00:00:00Z","timestamp":1705708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Health Science and Technology Project Foundation of Zhejiang Province","award":["2016KYB011"],"award-info":[{"award-number":["2016KYB011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-invasive identification of breast cancer (BCa) patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is critical to determine appropriate surgical strategies and guide the resection range of tumor. This study aimed to examine the effectiveness of a nomogram created by combining radiomics signatures from both intratumoral and derived tissues with clinical characteristics for predicting pCR after NACT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The clinical data of 133 BCa patients were analyzed retrospectively and divided into training and validation sets. The radiomics features for Intratumoral, peritumoral, and background parenchymal enhancement (BPE) in the training set were dimensionalized. Logistic regression analysis was used to select the optimal feature set, and a radiomics signature was constructed using a decision tree. The signature was combined with clinical features to build joint models and generate nomograms. The area under curve (AUC) value of receiver operating characteristic (ROC) curve was then used to assess the performance of the nomogram and independent predictors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among single region, intratumoral had the best predictive value. The diagnostic performance of the intratumoral improved after adding the BPE features. The AUC values of the radiomics signature were 0.822 and 0.82 in the training and validation sets. Multivariate logistic regression analysis revealed that age, ER, PR, Ki-67, and radiomics signature were independent predictors of pCR in constructing a nomogram. The AUC of the nomogram in the training and validation sets were 0.947 and 0.933. The DeLong test showed that the nomogram had statistically significant differences compared to other independent predictors in both the training and validation sets (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>BPE has value in predicting the efficacy of neoadjuvant chemotherapy, thereby revealing the potential impact of tumor growth environment on the efficacy of neoadjuvant chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12880-024-01198-4","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T14:02:08Z","timestamp":1705759328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prediction of neoadjuvant chemotherapy pathological complete response for breast cancer based on radiomics nomogram of intratumoral and derived tissue"],"prefix":"10.1186","volume":"24","author":[{"given":"Guangying","family":"Zheng","sequence":"first","affiliation":[]},{"given":"Jie","family":"Hou","sequence":"additional","affiliation":[]},{"given":"Zhenyu","family":"Shu","sequence":"additional","affiliation":[]},{"given":"Jiaxuan","family":"Peng","sequence":"additional","affiliation":[]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[]},{"given":"Zhongyu","family":"Yuan","sequence":"additional","affiliation":[]},{"given":"Xiaodong","family":"He","sequence":"additional","affiliation":[]},{"given":"Xiangyang","family":"Gong","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,1,20]]},"reference":[{"issue":"5","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1055-9965.EPI-20-1193","volume":"30","author":"SC Houghton","year":"2021","unstructured":"Houghton SC, Hankinson SE. Cancer progress and priorities: breast cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(5):822\u201344.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1130","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.","journal-title":"Br J Radiol"},{"key":"1198_CR3","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordstr\u00f6m E, Bliss J, Boccardo F, Boddington C, Bogaerts J, Bonadonna G, Bradley R, Brain E, Braybrooke J, Broet P, Bryant J, Burrett J, Cameron D, Clarke M, Coates A, Coleman R, Coombes RC, Correa C, Costantino J, Cuzick J, Danforth D, Davidson N, Davies C, Davies L, Di Leo A, Dodwell D, Dowsett M, Duane F, Evans V, Ewertz M, Fisher B, Forbes J, Ford L, Gazet JC, Gelber R, Gettins L, Gianni L, Gnant M, Godwin J, Goldhirsch A, Goodwin P, Gray R, Hayes D, Hill C, Ingle J, Jagsi R, Jakesz R, James S, Janni W, Liu H, Liu Z, Lohrisch C, Loibl S, MacKinnon L, Makris A, Mamounas E, Mannu G, Mart\u00edn M, Mathoulin S, Mauriac L, McGale P, McHugh T, Morris P, Mukai H, Norton L, Ohashi Y, Olivotto I, Paik S, Pan H, Peto R, Piccart M, Pierce L, Poortmans P, Powles T, Pritchard K, Ragaz J, Raina V, Ravdin P, Read S, Regan M, Robertson J, Rutgers E, Scholl S, Slamon D, S\u00f6lkner L, Sparano S, Steinberg S, Sutcliffe R, Swain S, Taylor C, Tutt A, Valagussa P, van de Velde C, van der Hage J, Viale G, von Minckwitz G, Wang Y, Wang Z, Wang X, Whelan T, Wilcken N, Winer E, Wolmark N, Wood W, Zambetti M, Zujewski JA. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27\u201339.","DOI":"10.1016\/S1470-2045(17)30777-5"},{"issue":"9","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/14656566.2020.1746273","volume":"21","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Nuzzolese I, Ponzone R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? Expert Opin Pharmacother. 2020;21(9):1071\u201382.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1198_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2967\/jnumed.118.222893","volume":"61","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Materka A, Langs G, H\u00e4ggstr\u00f6m I, Szczypi\u0144ski P, Gibbs P, Cook G. Introduction to radiomics. J Nucl Med. 2020;61(4):488\u201395.","journal-title":"J Nucl Med"},{"issue":"12","key":"1198_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue R, Even AJG, Jochems A, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-18-3427","volume":"25","author":"H Nakshatri","year":"2019","unstructured":"Nakshatri H, Kumar B, Burney HN, Cox ML, Jacobsen M, Sandusky GE, D\u2019Souza-Schorey C, Storniolo AMV. Genetic ancestry-dependent differences in breast cancer-induced field defects in the tumor-adjacent normal breast. Clin Cancer Res. 2019;25(9):2848\u201359.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"e192561","DOI":"10.1001\/jamanetworkopen.2019.2561","volume":"2","author":"N Braman","year":"2019","unstructured":"Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-positive breast cancer. JAMA Netw Open. 2019;2(4):e192561.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1198_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13058-017-0846-1","volume":"19","author":"NM Braman","year":"2017","unstructured":"Braman NM, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P, Plecha D, Madabhushi A. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 2017;19(1):57.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1148\/radiol.2021203645","volume":"301","author":"N Onishi","year":"2021","unstructured":"Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, et al. Breast MRI during neoadjuvant chemotherapy: lack of background parenchymal enhancement suppression and inferior treatment response. Radiology. 2021;301(2):295\u2013308.","journal-title":"Radiology"},{"issue":"1","key":"1198_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1148\/radiol.11102156","volume":"260","author":"V King","year":"2011","unstructured":"King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology. 2011;260(1):50\u201360.","journal-title":"Radiology"},{"issue":"1","key":"1198_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jmri.26762","volume":"51","author":"GJ Liao","year":"2020","unstructured":"Liao GJ, Henze Bancroft LC, Strigel RM, Chitalia RD, Kontos D, Moy L, Partridge SC, Rahbar H. Background parenchymal enhancement on breast MRI: a comprehensive review. J Magn Reson Imaging. 2020;51(1):43\u201361.","journal-title":"J Magn Reson Imaging"},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clinimag.2021.11.021","volume":"83","author":"E Bauer","year":"2022","unstructured":"Bauer E, Levy MS, Domachevsky L, Anaby D, Nissan N. Background parenchymal enhancement and uptake as breast cancer imaging biomarkers: a state-of-the-art review. Clin Imaging. 2022;83:41\u201350.","journal-title":"Clin Imaging"},{"issue":"4","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3390\/curroncol28040217","volume":"28","author":"F Pesapane","year":"2021","unstructured":"Pesapane F, Rotili A, Agazzi GM, Botta F, Raimondi S, Penco S, Dominelli V, Cremonesi M, Jereczek-Fossa BA, Carrafiello G, et al. Recent radiomics advancements in breast cancer: lessons and pitfalls for the next future. Curr Oncol. 2021;28(4):2351\u201372.","journal-title":"Curr Oncol"},{"issue":"9","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206\u201323.","journal-title":"Ann Oncol"},{"issue":"1","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13058-018-0975-1","volume":"20","author":"Q Zhu","year":"2018","unstructured":"Zhu Q, Tannenbaum S, Kurtzman SH, DeFusco P, Ricci A Jr, Vavadi H, Zhou F, Xu C, Merkulov A, Hegde P, et al. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters. Breast Cancer Res. 2018;20(1):56.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/jpm11040256","volume":"11","author":"D La Forgia","year":"2021","unstructured":"La Forgia D, Vestito A, Lasciarrea M, Comes MC, Diotaiuti S, Giotta F, Latorre A, Lorusso V, Massafra R, Palmiotti G, et al. Response predictivity to neoadjuvant therapies in breast cancer: a qualitative analysis of background parenchymal enhancement in DCE-MRI. J Pers Med. 2021;11(4):256.","journal-title":"J Pers Med"},{"issue":"5","key":"1198_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1053\/j.semdp.2022.06.015","volume":"39","author":"Y Hou","year":"2022","unstructured":"Hou Y, Peng Y, Li Z. Update on prognostic and predictive biomarkers of breast cancer. Semin Diagn Pathol. 2022;39(5):322\u201332.","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10549-021-06294-5","volume":"189","author":"M Abubakar","year":"2021","unstructured":"Abubakar M, Guo C, Koka H, Zhu B, Deng J, Hu N, Zhou B, Garcia-Closas M, Lu N, Yang XR. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer. Breast Cancer Res Treat. 2021;189(2):483\u201395.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607\u201317.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1198_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/2159-8290.CD-17-0228","volume":"7","author":"AL Guerrero-Zotano","year":"2017","unstructured":"Guerrero-Zotano AL, Arteaga CL. Neoadjuvant trials in ER(+) breast cancer: a tool for acceleration of drug development and discovery. Cancer Discov. 2017;7(6):561\u201374.","journal-title":"Cancer Discov"},{"issue":"10","key":"1198_CR22","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","volume":"35","author":"MJ Ellis","year":"2017","unstructured":"Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (Alliance). J Clin Oncol. 2017;35(10):1061\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1198_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s00259-020-04684-3","volume":"47","author":"P Li","year":"2020","unstructured":"Li P, Wang X, Xu C, Liu C, Zheng C, Fulham MJ, Feng D, Wang L, Song S, Huang G. (18)F-FDG PET\/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(5):1116\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1245\/s10434-022-11367-w","volume":"29","author":"FC Verdial","year":"2022","unstructured":"Verdial FC, Mamtani A, Pawloski KR, Sevilimedu V, D\u2019Alfonso TM, Zhang H, Gemignani ML, Barrio AV, Morrow M, Tadros AB. The Effect of age on outcomes after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2022;29(6):3810\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"1198_CR25","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.3390\/cancers13174271","volume":"13","author":"F Pesapane","year":"2021","unstructured":"Pesapane F, Rotili A, Botta F, Raimondi S, Bianchini L, Corso F, Ferrari F, Penco S, Nicosia L, Bozzini A, et al. Radiomics of MRI for the prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients: a single referral centre analysis. Cancers (Basel). 2021;13(17):4271.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.diii.2020.05.010","volume":"101","author":"R Rella","year":"2020","unstructured":"Rella R, Bufi E, Belli P, Petta F, Serra T, Masiello V, Scrofani AR, Barone R, Orlandi A, Valentini V, et al. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy. Diagn Interv Imaging. 2020;101(10):649\u201355.","journal-title":"Diagn Interv Imaging"},{"issue":"3","key":"1198_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.diii.2015.12.006","volume":"97","author":"M Telegrafo","year":"2016","unstructured":"Telegrafo M, Rella L, Stabile Ianora AA, Angelelli G, Moschetta M. Effect of background parenchymal enhancement on breast cancer detection with magnetic resonance imaging. Diagn Interv Imaging. 2016;97(3):315\u201320.","journal-title":"Diagn Interv Imaging"},{"issue":"1","key":"1198_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1148\/radiol.220440","volume":"306","author":"SH Lee","year":"2023","unstructured":"Lee SH, Jang MJ, Yoen H, Lee Y, Kim YS, Park AR, Ha SM, Kim SY, Chang JM, Cho N, et al. Background parenchymal enhancement at postoperative surveillance breast MRI: association with future second breast cancer risk. Radiology. 2023;306(1):90\u20139.","journal-title":"Radiology"},{"key":"1198_CR29","doi-asserted-by":"publisher","first-page":"110247","DOI":"10.1016\/j.ejrad.2022.110247","volume":"150","author":"X Liang","year":"2022","unstructured":"Liang X, Yu X, Gao T. Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Eur J Radiol. 2022;150:110247.","journal-title":"Eur J Radiol"},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"106510","DOI":"10.1016\/j.cmpb.2021.106510","volume":"214","author":"XX Yin","year":"2022","unstructured":"Yin XX, Hadjiloucas S, Zhang Y, Tian Z. MRI radiogenomics for intelligent diagnosis of breast tumors and accurate prediction of neoadjuvant chemotherapy responses-a review. Comput Methods Programs Biomed. 2022;214:106510.","journal-title":"Comput Methods Programs Biomed"},{"key":"1198_CR31","doi-asserted-by":"publisher","first-page":"103460","DOI":"10.1016\/j.ebiom.2021.103460","volume":"69","author":"Y Yu","year":"2021","unstructured":"Yu Y, He Z, Ouyang J, Tan Y, Chen Y, Gu Y, Mao L, Ren W, Wang J, Lin L, et al. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: a machine learning, multicenter study. EBioMedicine. 2021;69:103460.","journal-title":"EBioMedicine"},{"issue":"2","key":"1198_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-018-4990-9","volume":"173","author":"EH Cain","year":"2019","unstructured":"Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Res Treat. 2019;173(2):455\u201363.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1198_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12938-021-00899-z","volume":"20","author":"L Hussain","year":"2021","unstructured":"Hussain L, Huang P, Nguyen T, Lone KJ, Ali A, Khan MS, Li H, Suh DY, Duong TQ. Machine learning classification of texture features of MRI breast tumor and peri-tumor of combined pre- and early treatment predicts pathologic complete response. Biomed Eng Online. 2021;20(1):63.","journal-title":"Biomed Eng Online"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-024-01198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-024-01198-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-024-01198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T14:02:16Z","timestamp":1705759336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-024-01198-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1186\/s12880-024-01198-4","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study complied with the Declaration of Helsinki. This retrospective study was approved by the Ethics Committee of Zhejiang Provincial People\u2019s Hospital (Gongshu, P.R. China)\u00a0(No. QT2023380), and the need for informed consent was exempted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}